Clinical trial · Observational
Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population
Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population Treated With Immune Checkpoint Inhibitors for Various Cancers
NCT05863052CI-TRIAL-00102927active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 19, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260919-000001
Summary
Brief summary (as posted)
The aim of this study is to describe the outcomes in American Indian patients receiving immunotherapy in a multi-institution retrospective study at several other high-volume centers that care for this patient population and to identify any healthcare disparities that can lead to future interventional studies.
Conditions
Conditions (7)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastrointestinal Cancer | Malignant Digestive System Neoplasm | ALIAS | 0.90 |
| Immune Checkpoint Inhibitors | — | UNRESOLVED | — |
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
| Metastatic Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
| Nonsmall Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
| Squamous Cell Carcinoma | Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Immunotherapy | Biological | Immunotherapy | ALIAS |
Design
Arms and outcomes
Arms (2)
- label
- American Indian population
- interventionNames
- Biological: Immunotherapy
- label
- Caucasians treated with immunotherapy
- interventionNames
- Biological: Immunotherapy
Primary outcomes (3)
- measure
- Progression Free Survival
- timeFrame
- 1 year
- description
- Evaluating progression free survival of American Indian population vs. White population who were treated with immunotherapy
- measure
- Overall Survival Benefit
- timeFrame
- 1 year
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * above age 18, * histologically and cytologically confirmed NSCLC, melanoma, head and neck squamous cell carcinoma, gastrointestinal cancers,, renal cell carcinoma, or any other solid tumors where immune checkpoint therapy has been used * received immunotherapy as part of their treatment * Self-identified American Indian in ethnicity * Patients at the Stephenson Cancer Center between 2015 to 2021 Exclusion Criteria: * patients who did not receive immune checkpoint inhibitor therapy
References
Publications (0)
Data not yet available
No reference posted for this study.